Tablets, Lozenges, Or Pills Patents (Class 424/464)
  • Patent number: 9629894
    Abstract: Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: April 25, 2017
    Assignee: TRIGEMINA, INC.
    Inventors: David C. Yeomans, Dean Carson, Ramachandran Thirucote
  • Patent number: 9633575
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: April 25, 2017
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 9629915
    Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: April 25, 2017
    Assignee: Rubicon Research Private Limited
    Inventors: Pratibha S Pilgaonkar, Maharukh T Rustomjee, Anilkumar S Gandhi, Paras R Jain, Atul A Kelkar
  • Patent number: 9622967
    Abstract: Disclosed are highly stable compositions having outstanding storage stability and/or demonstrating exceptional resistance to aqueous solution degradation, the composition including an orally active nucleotide analog or an orally active nucleotide analog prodrug, which is orally bioavailable, such as adefovir dipivoxil and tenofovir disoproxil. For example, when a composition of the invention is stored for 1 month or for 18 months at 25° C. and 60% relative humidity, its orally active nucleotide analog or orally active nucleotide analog prodrug degrades to provide a composition containing no more than 0.2% or no more than 0.7% by weight of a less orally bioavailable impurity, respectively. Also disclosed are a container/closure package system including the composition and a package insert and methods of manufacturing the composition and treating a patient for a disease or condition, for example, a viral disease or cancer, with the use of the composition.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: April 18, 2017
    Assignee: Sigmapharm Laboratories, LLC
    Inventors: Spiridon Spireas, Ishari Piya, Rakesh Grover, Sunil Sagi, Ram K. Kallur
  • Patent number: 9616026
    Abstract: Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: April 11, 2017
    Assignee: The Roshni Singh 2015 Trust
    Inventor: Bramah N. Singh
  • Patent number: 9610251
    Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: April 4, 2017
    Assignee: Resverlogix Corp.
    Inventor: Narmada R. Shenoy
  • Patent number: 9603806
    Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: March 28, 2017
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
  • Patent number: 9603794
    Abstract: The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 28, 2017
    Inventor: Mahmut Bilgic
  • Patent number: 9592646
    Abstract: A tablet for pharmaceutical use has on at least one part of its surface a diffractive microstructure which generates diffraction effects which can be perceived in the visible spectral range and which serve as visual safety feature. The tablet includes a plurality of individual powder particles, where the diffractive microstructures are impressed into the surface of the individual powder particles. A compression tool to produce such tablets has on one pressing surface of the compression tool micro-structures, where the microstructures have dimensions which are smaller than the dimensions of the individual crystallites of the material of the pressing surface of the compression tool. The micro-structures of the compression tool can be produced for example by ion etching or by imprinting.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: March 14, 2017
    Assignee: CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA
    Inventors: Alexander Stuck, Harald Walter, Marc Schnieper, Jürgen Söchtig, Christian Zschokke
  • Patent number: 9585845
    Abstract: A pharmaceutical composition, including: an active ingredient-loaded pellet core and a coating layer. The active ingredient of the pellet core is oseltamivir or a pharmaceutically acceptable salt thereof. The active ingredient accounts for between 10 and 40 wt. % of the total weight of the pharmaceutical composition. The coating layer includes a polyacrylic acid resin IV and accounts for between 1 and 50 wt. % of the total weight of the pharmaceutical composition. The pharmaceutical composition has a diameter of between 0.10 and 0.50 mm.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: March 7, 2017
    Assignee: Zhongshuai Pharmaceutical Sci & Tech Co., Ltd.
    Inventors: Weidong Sun, Fengxiao Ren
  • Patent number: 9572909
    Abstract: Nerve guides which are formed from three dimensional (3D) arrays of highly aligned electrospun fibers are provided. The electrospun fibers are oriented parallel to the long axis of the guide, and gaps and elongated spaces between the stacked fiber arrays provide channels for directed axonal growth. In some embodiments, the nerve guides also comprise high precision gradients of beneficial substances such as growth factors, which aid in nerve regeneration and growth along the guide.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: February 21, 2017
    Assignee: Virginia Commonwealth University
    Inventors: David Simpson, Gary Bowlin, Raymond Colello, Woon Chow, Balendu Shekhar Jha
  • Patent number: 9572784
    Abstract: Compositions and methods comprising at least one biguanide compound and at least one statin combined with at least one additional active agent in fixed dose combinations are provided for reducing cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the biguanide compound is formulated for delayed release.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: February 21, 2017
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Patent number: 9555122
    Abstract: Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: January 31, 2017
    Assignee: ethris GmbH
    Inventors: Carsten Rudolph, Johannes-Peter Geiger
  • Patent number: 9555056
    Abstract: The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 31, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Hitesh R. Bhagat, Jeffrey M. Goldberg, Abizer I. Harianawala, Louis Brenner
  • Patent number: 9545399
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: January 17, 2017
    Assignee: TRIS PHARMA, INC.
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 9539283
    Abstract: Disclosed is an effervescent preparation of calcium and magnesium with additional citric acid in a defined ratio. Also disclosed is the use of these compositions to raise cardioprotective citrate and magnesium in serum to help prevent heart attacks from calcium supplements, and to provide bioavailable calcium and magnesium to prevent osteoporosis-related fractures and low blood magnesium from the use of proton pump inhibitors.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: January 10, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Charles Y. C. Pak, Khashayar Sakhaee, Orson W. Moe
  • Patent number: 9539214
    Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: January 10, 2017
    Assignee: Pozen Inc.
    Inventor: John R. Plachetka
  • Patent number: 9532984
    Abstract: This invention relates to a synergistic pharmaceutical combination of glucose lowering drugs and autophagy inhibitors, kits containing such combinations, and methods of using such combinations to treat subjects suffering from cancers carrying a specific KRAS mutation. This invention also relates to a theranostic method for cancer treatment.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: January 3, 2017
    Assignee: The Translational Genomics Research Institute
    Inventor: Stephen T. Gately
  • Patent number: 9532955
    Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: January 3, 2017
    Assignees: Kala Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Alexey Popov, Elizabeth M. Enlow, James Bourassa, Colin R. Gardner, Hongming Chen, Laura M. Ensign, Samuel K. Lai, Tao Yu, Justin Hanes, Ming Yang
  • Patent number: 9526789
    Abstract: Disclosed are an oral formulation which disintegrates quickly in the oral cavity; a fast-disintegrating tablet having fast disintegrability and high hardness, and a process for manufacturing the same. In addition, slightly wetted granules for manufacturing said fast-disintegrating tablet and a process for manufacturing the same are disclosed.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: December 27, 2016
    Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
    Inventors: Sang Yeob Park, Hye Jung Lim
  • Patent number: 9511028
    Abstract: The present invention features a tablet containing at least one first material, at least one second material, and at least one pharmaceutically active agent, wherein: (a) the first material is a dielectric water-containing material (i) containing from about 1 to about 5 percent, by weight, of bound water and (ii) having a dielectric loss, when measured at a density of between 0.15 and 0.5 g/cc, of from about 0.05 to about 0.7; and (b) the second material (i) having a water solubility from about 20 to about 400 g per 100 g of water at 25° C., (ii) having a dielectric loss, when measured at a density between 0.5 and 1 g/cc, of less than about 0.05.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 6, 2016
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Jen-Chi Chen, Kenneth Day, Christopher E. Szymczak
  • Patent number: 9511147
    Abstract: This invention relates to compositions and applications for an mterpolymer network delivery system containing iodine.
    Type: Grant
    Filed: August 12, 2012
    Date of Patent: December 6, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Joachim B. Kohn, Carmine P. Iovine, Niraj Ramachandran
  • Patent number: 9505708
    Abstract: The invention relates to a new process for the production and/or purification of the salt of the compound (S)-2-[4-(2-fluorobenzyloxy) benzylamino]propanamide, i.e. ralfinamide, or the respective R-enantiomer, with methane sulfonic acid in high yields and very high enantiomeric and chemical purity in the form of the crystalline anhydrous polymorph identified as form A, wherein said salt is substantially free from impurities having genotoxic effect, such as (C1-C5)alkanylmethanesulfonates, and residual solvents known as potential precursors thereof, such as (C1-C5)alkanols or esters thereof with lower alkanoic acids.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: November 29, 2016
    Assignee: NEWRON PHARMACEUTICALS S.P.A.
    Inventors: Claudio Giordano, Erwin Waldvogel
  • Patent number: 9498445
    Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: November 22, 2016
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
  • Patent number: 9492390
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 15, 2016
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9492380
    Abstract: A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: November 15, 2016
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Lauren Beach, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant
  • Patent number: 9486412
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 8, 2016
    Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Patent number: 9468610
    Abstract: The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: October 18, 2016
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventor: Hagen Kruger
  • Patent number: 9463170
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: October 11, 2016
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Nigel R. A. Beeley, Mark S. Fineman
  • Patent number: 9457032
    Abstract: A therapeutic agent for renal failure including, as an active ingredient, a 4,8-inter-m-phenylene prostaglandin I2 derivative, and also a method for treatment of renal failure using the same.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: October 4, 2016
    Assignee: Toray Industries, Inc.
    Inventors: Hajimu Kurumatani, Motohiro Suzuki
  • Patent number: 9446037
    Abstract: Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 20, 2016
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Roger Mills, Hilde Williams
  • Patent number: 9446002
    Abstract: The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of which include at least 8 carbon atoms; and (iii) an outer water-dispersible layer containing at least one disintegrating agent. The invention further relates to multiparticular tablets comprising said spheroids.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: September 20, 2016
    Assignee: ETHYPHARM
    Inventors: Philippe Chenevier, Dominique Marechal
  • Patent number: 9439936
    Abstract: The invention relates to Boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: articular cartilage degradation or arthritides, osteoarthritis, rheumatoid arthritis, inflammatory bowel disease (IBD), all forms of muscular dystrophy especially Duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, Alzheimer's Disease, demyelinating neurological disorders including multiple sclerosis, Acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: September 13, 2016
    Assignee: COMPTON DEVELOPMENTS LTD.
    Inventors: Emma Jane Blain, Victor Collin Duance, Ahmed Yasine Ali, Ifor Delme Bowen
  • Patent number: 9439865
    Abstract: A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: September 13, 2016
    Assignee: ASAHI KASEI CHEMICALS CORPORATION
    Inventors: Naoya Yoshida, Kazuhiro Obae
  • Patent number: 9439903
    Abstract: The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to pharmaceutical compositions that includes the stable amorphous imatinib messylate together along with its excipients.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: September 13, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Kumar Kamlesh Singh, Ganpant Dan Shimbu Charan, Chetan Jayantibhai Vasava
  • Patent number: 9433632
    Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: September 6, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Kawano, Yasushi Mima, Yumiko Ishii
  • Patent number: 9433625
    Abstract: Methods and compositions are provided which comprise effective amounts of one or more analgesics, such as hydrocodone or acetaminophen, and an antiemetic, such as promethazine, to treat or prevent pain in a subject, and to reduce or prevent an adverse effect associated with the analgesics.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: September 6, 2016
    Assignee: LOCL PHARMA, INC.
    Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
  • Patent number: 9415134
    Abstract: The invention relates to a fosfomycin preparation that comprises a) a calcium salt of fosfomycin and b) at least one sugar alcohol having a melting point above 70° C., whereby the weight ratio of sugar alcohol to calcium salt of fosfomycin is at least 0.8. Moreover, the invention proposes a method for producing the fosfomycin preparation and a polymethylmethacrylate bone cement powder that contains the fosfomycin preparation.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: August 16, 2016
    Assignee: HERAEUS MEDICAL GMBH
    Inventor: Sebastian Vogt
  • Patent number: 9402799
    Abstract: The invention relates to a sterilized composition comprising at least one hyaluronic acid or biologically acceptable salt thereof, alone or in a mixture, and magnesium ascorbyl phosphate, in a ratio [HA]/[MAP] by mass of the amount of hyaluronic acid or salt thereof [HA] to the amount of magnesium ascorbyl phosphate [MAP] of greater than or equal to 1, the amount of magnesium ascorbyl phosphate being between 0.001% and 1% by weight, relative to the total weight of said composition, with an elastic component G? which is retained or improved after sterilization and is between 5 and 400 Pa. It also relates to a composition of the invention which further includes dimethyl sulfone, to methods for producing same, and to uses thereof.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: August 2, 2016
    Assignee: LABORATORIES VIVACY
    Inventors: Jeremie Bon Betemps, Estelle Piron
  • Patent number: 9399066
    Abstract: The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: July 26, 2016
    Assignee: Novartis AG
    Inventors: Colleen Ruegger, Michael Ambuhl
  • Patent number: 9393213
    Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: July 19, 2016
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Alexey Popov, Elizabeth Enlow, James Bourassa, Colin R Gardner, Hongming Chen, Laura M Ensign, Samuel K Lai, Tao Yu, Justin Hanes, Ming Yang
  • Patent number: 9393212
    Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: July 19, 2016
    Assignee: Kala Pharmaceuticals, Inc.
    Inventors: Alexey Popov, Elizabeth Enlow, James Bourassa, Colin R Gardner, Hongming Chen, Laura M Ensign, Samuel K Lai, Tao Yu, Justin Hanes, Ming Yang
  • Patent number: 9393192
    Abstract: Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: July 19, 2016
    Inventors: Nyomi V. Yam, Iran Reyes, Nipun Davar, Atul D. Ayer, Julie Lee, Sonya Seroff, Suneel K. Gupta, Gayatri Sathyan
  • Patent number: 9370577
    Abstract: The present invention relates to stable pharmaceutical compositions comprising entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts or hydrates thereof. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: June 21, 2016
    Assignee: WOCKHARDT LIMITED
    Inventors: Sudhir Goswami, Mahesh Rameshwar Kalantri, Asif Mohammad, Narayanan Murali, Girish Kumar Jain
  • Patent number: 9358264
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: June 7, 2016
    Assignee: NATUREX, S.A.
    Inventors: Alvin Ibarra, Marc Roller, Jacques DiKansky
  • Patent number: 9352012
    Abstract: The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: May 31, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
  • Patent number: 9347947
    Abstract: Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: May 24, 2016
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Pratap Singh, Yi Feng Zheng, Liping Geng, Roland Janzen, Carsten Schelp
  • Patent number: 9339470
    Abstract: A pharmaceutical composition comprising a solid unit dosage form comprising: (i) ritonavir or a pharmaceutically acceptable salt and ester thereof; (ii) darunavir or a pharmaceutically acceptable salt and ester thereof.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: May 17, 2016
    Assignee: Cipla Limited
    Inventors: Amar Lulla, Geena Malhotra
  • Patent number: 9339504
    Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: May 17, 2016
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
  • Patent number: 9326982
    Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 3, 2016
    Assignee: Pemix Ireland Pain Limited
    Inventors: Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson